Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Get Free Report) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 37,127 shares, a decline of 53.9% from the July 15th total of 80,592 shares. Based on an average daily trading volume, of 138,153 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.7% of the shares of the company are sold short.
Regentis Biomaterials Price Performance
NYSEAMERICAN:RGNT traded up $0.05 during trading hours on Monday, hitting $2.05. 28,468 shares of the company traded hands, compared to its average volume of 2,230,555. The firm has a 50-day moving average of $2.97 and a 200 day moving average of $3.16. Regentis Biomaterials has a twelve month low of $1.23 and a twelve month high of $15.50.
Hedge Funds Weigh In On Regentis Biomaterials
A hedge fund recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC bought a new stake in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned 5.79% of Regentis Biomaterials as of its most recent SEC filing.
Regentis Biomaterials Company Profile
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.
See Also
- Five stocks we like better than Regentis Biomaterials
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Regentis Biomaterials Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regentis Biomaterials and related companies with MarketBeat.com's FREE daily email newsletter.
